MD FAAP, Herbert Irving Associate Professor of Pediatrics, Chief of Pediatric Neuro-Oncology, Columbia University Medical Center, New York

Stergios Zacharoulis

Dr Stergios Zacharoulis is currently Chief of  Pediatric Neuro-Oncology and Associate Professor of Pediatrics  at Columbia University Medical Center specializing in brain spine and neural malignancies of childhood. He is an American Board Certified Pediatrician (trained at Yale and SUNY at Syracuse) and Pediatric Oncologist (trained at Memorial Sloan-Kettering Cancer Center, New York). Dr Zacharoulis sub-specialized further in Neuro-Oncology (brain, spinal cord and neurogenic tumors) at Children’s Hospital Boston, Harvard Medical School. He was appointed Assistant Professor of Pediatric Oncology at Keck School Of Medicine, University of Southern California, Childrens Hospital Los Angeles and was lead Pediatric Neuro-Oncologist for a decade at the Royal Marsden NHS Trust and The Harley Street Clinic in London, UK where he established the single European program performing  Convection Enhanced Deliver for children with diffuse intrinsic pontine glioma  before returning to the US.

His main interests include novel drug delivery methods for inoperable brain tumors and precision medicine in neuro-oncology using novel agents. His research efforts are focusing on innovative   methods that improve drug delivery in brain tumors , such as chronic infusion of medicines directly into the tumor through skin implanted catheters under the skin in collaboration with the neurosurgical team at Columbia   ( Convection Enhanced Delivery ) and pioneering the us non-invasive methods to disrupt the blood brain barrier by focused ultrasound in collaboration with the Radiation oncology and Biomedical Engineering departments at Columbia   , allowing higher concentrations of drugs into the brain minimizing the side effects .He is also leading a  global effort to identify new targets for fatal tumors such diffuse midline glioma and ependymoma  in collaboration with the  System Biology Department .  Also his work is focusing on evaluating  novel technology to predict response to treatment and allow personalized approach in a timely fashion based on very rapid drug and molecular screening  in collaboration with our Neuropathology department at CUMC.

His bibliography includes several original papers in peer review journals and book chapters, and he has been an invited speaker about brain tumors at international meetings.